Kenvue Q3 2026 earnings

KVUE · 2026-10-30 06:49 BMO ET · 8-K on SEC · 10-Q on SEC

Net sales grew 3.2% with organic growth of 2.9%, while adjusted operating income margin expanded 0.4 pp to 21.9%.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$3.89B+3.2%—Ex. 99.1, income statement
EPS (GAAP)$0.22+5%—Ex. 99.1, income statement
EPS (adjusted)$0.29+4%—Ex. 99.1, income statement
Net income$430M+8%—Ex. 99.1, income statement
Adj. EBITDA$920M+8%—Ex. 99.1, income statement
Adj. EBITDA margin23.7%+2.1 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Self Care$3.89B+5.9%50%Organic growth 5.4%
Skin Health and Beauty$3.89B+0.1%50%Organic decline 0.5%
Essential Health$3.89B+2.5%50%Organic growth 2.5%

Margins and costs

  • Gross margin 59.5% (prior 59.1%, change +0.4 pp)
  • Operating expenses $1.57B (+4%)
  • One-offs in the quarter Restructuring expenses $33M; Pending Transaction and other related costs $28M; Separation-related costs $6M; Skillman sale-leaseback $2M
  • Effective tax rate 29.4% (prior-year 24.3%, year-to-date 29.4%)
  • Non-GAAP bridge Adds back amortization of intangible assets, restructuring expenses, operating model optimization initiatives, Separation-related costs, conversion of stock-based awards, Founder Shares, Pending Transaction and other related costs, and Skillman sale-leaseback; excludes Deferred Markets.

KPIs

MetricActualPrior quarterPrior yearChange
Free cash flow$1.6B$1.0B$1.0B+60%
Net cash flows from operating activities$1.9B$1.2B$1.3B+46%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Net sales increased 3.2% driven by organic sales growth of 2.9% and a foreign currency benefit of 0.3%.
  • EPS story Diluted EPS increased 5% to $0.22, with adjusted EPS increasing 4% to $0.29.
  • One-off check Restructuring expenses $33M (2026 Restructuring Initiative); Pending Transaction and other related costs $28M; Separation-related costs $6M; Skillman sale-leaseback $2M.

The good

  • Fourth consecutive quarter of net and organic sales growth
  • Adjusted operating income margin expanded 0.4 pp to 21.9%
  • Free cash flow increased to $1.6B

The bad

  • Skin Health and Beauty net sales flat vs prior year
  • Adjusted gross profit margin 61.5% vs 61.2% prior year

The ugly

  • none

Open questions

  • How will the pending transaction with Kimberly-Clark impact future operations and guidance?
  • What specific factors drove the year-over-year increase in the effective tax rate to 29.4%?
Full release

Kenvue (KVUE) earnings release, October 30, 2026

Kenvue Inc. (KVUE) · Form 8-K, Item 2.02 · Filed · SEC filing

Kenvue Reports Third

Quarter 2026 Results

• Delivered Fourth Consecutive Quarter of Net and Organic Sales¹

Growth

• Net Sales Increased 3.2%; Organic Sales

Increased 2.9%

• Diluted EPS Increased 5% to $0.22; Adjusted Diluted EPS¹

Increased 4% to $0.29

SUMMIT, N.J. October 30, 2026 – Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal third quarter ended September 27, 2026.

“We are pleased to have delivered our fourth consecutive quarter of net and organic sales growth, with strong performance in Self Care and Essential Health, along with margin expansion and strong cash generation,” said Kirk Perry, Chief Executive Officer. “Our results reflect continued momentum from disciplined execution, ongoing productivity initiatives, and investment in our brands and innovation. We are strongly on track to deliver our business transformation that we began last year. I want to thank our entire organization for their dedication to delighting our consumers and customers, disciplined execution, and delivering what was promised.”

Perry continued, “As we near the completion of our value-creating combination with Kimberly-Clark and bring together our two companies, the team is excited about the opportunities ahead.”

Third Quarter Summary

• Net sales increased

3.2% vs the prior year period, reflecting Organic sales growth of 2.9% and a foreign currency benefit of 0.3%.

• Gross profit margin was 59.5% vs 59.1% in the prior year period. Adjusted gross profit margin¹ was 61.5% vs 61.2% in the prior year period.

• Operating income margin was 18.2% vs 16.7% in the prior year period. Adjusted operating income margin¹ was 21.9% vs 21.5% in the prior year period.

• Diluted earnings per share were $0.22 vs $0.21 in the prior year period. Adjusted diluted earnings per share¹ were $0.29 vs $0.28 in the prior year period.

• Due to the pending transaction with Kimberly-Clark, the Company will not be providing forward-looking guidance.¹

Third Quarter 2026 Financial Results

Net Sales and Organic Sales

Third quarter 2026 Net sales increased

3.2% vs the prior year period, primarily reflecting Organic sales growth of 2.9% and a foreign currency benefit of 0.3%. Organic sales growth was driven by volume growth of 1.6% and favorable value realization of 1.3%.

Gross Profit Margin and Operating Income Margin

Third quarter 2026 Gross profit margin was 59.5% vs 59.1% in the prior year period. Adjusted gross profit margin was 61.5% vs 61.2% in the prior year period. The year-over-year change in both measures primarily reflects savings from productivity gains attributable to our global supply chain optimization initiatives, U.S. tariff refunds, and favorable value realization, partially offset by the impact from inflation as well as unfavorable transactional foreign exchange.

Third quarter 2026 Operating income margin was 18.2% vs 16.7% in the prior year period. Third quarter 2026 Adjusted operating income margin was 21.9% vs 21.5% in the prior year period. The year-over-year change in both measures reflects the year-over-year change in Gross profit margin and Adjusted gross profit margin, as well as savings from our cost optimization actions, including the 2026 Restructuring Initiative and Our Vue Forward, partially offset by a year-over-year increase in brand support.

Interest Expense, Net and Taxes

Third quarter 2026 Interest expense, net was $89 million vs $93 million in the prior year period.

Third quarter Effective tax rate was 29.4% vs 24.3% in the prior year period. The Adjusted effective tax rate¹ was 24.7% in the current period vs 24.0% in the prior year period. The year-over-year increase in both measures largely reflects a reduction in favorable discrete return-to-provision adjustments as compared to the prior year, partially offset by the impact of tax law changes.

Net Income Per Share (“Earnings Per Share”)

Third quarter 2026 Diluted earnings per share were $0.22 vs $0.21 in the prior year period. Adjusted diluted earnings per share were $0.29 in the current period vs $0.28 in the prior year period.²

Third Quarter 2026 Business Segment Results

Self Care

Third quarter 2026 Net sales increased 5.9% vs the prior year period, reflecting Organic sales growth of 5.4% and a foreign currency benefit of 0.5%. Organic sales growth was driven by a volume increase of 3.4% and favorable value realization of 2.0%. Organic sales increased in Asia Pacific (“APAC”), benefiting from favorable inventory-related comparisons following prior year trade inventory depletion, while strong innovation and commercial execution in Pain Care enabled Motrin® to outperform the market as the region experienced rising flu incidences. Smoking Cessation delivered low double-digit Organic sales growth in the quarter, led by Europe, Middle East, and Africa (“EMEA”) and APAC, reflecting strong demand and commercial execution for Nicorette®. Pepcid® continued to outperform the category, benefitting from strong commercial and innovation-led initiatives. In the U.S., consumption trends improved sequentially, and Tylenol® gained market share despite lower seasonal incidences versus the prior year period and continued category softness.

Skin Health and Beauty

Third quarter 2026 Net sales increased 0.1% vs the prior year period, reflecting Organic sales decline of 0.5% and a foreign currency benefit of 0.6%. Organic sales decline was driven by a volume decrease of 1.7%, partially offset by favorable value realization of 1.2%. Organic sales declined vs the prior year period reflecting distribution losses and timing of promotions in the U.S. and the impact of retailer negotiations in Europe. Hair Care was a key growth driver during the quarter, delivering low double-digit Organic sales growth, led by Rogaine®, which achieved its fourth consecutive quarter of market share gains, and continued momentum behind OGX®... (truncated) the expansion of North America Sun Care with the launch of Neutrogena®

Cloud Tech

TM featuring BEMT (bemotrizinol) and the brand's proprietary technology, continued expansion of Neutrogena®

Ultra Sheer®

Sun, and momentum behind OGX®

ProGrowth and ProGrowth + Peptide platforms.

Essential Health

Third quarter 2026 Net sales increased 2.5% vs the prior year period, reflecting Organic sales growth of 2.5%. Organic sales growth was driven by a volume increase of 2.0% and favorable value realization of 0.5% with growth across all regions. Baby Care delivered growth for the quarter driven by Johnson’s Baby® across all regions supported by social commerce acceleration, strong activations, and innovation. Women’s Health also contributed to growth, led by Stayfree®, which benefited from recent product launches in India, and o.b.®, which returned to growth in EMEA following its brand restage and pricing actions. Wound Care continued to gain market share, supported by BAND-AID®

Brand PRO HEAL®

5 Day Protect, distribution expansion, and retailer³ activations. Innovation remained a key growth driver, including Stayfree®

Secure Nights and XpertXL in India, the ongoing rollout of Listerine®

On-The-Go mouthwash packets, and Johnson’s Baby® innovations in Latin America.

Cash Flow and Balance Sheet

Fiscal nine months ended September 27, 2026 Net cash flows from operating activities were $1.9 billion vs $1.3 billion in the prior year period, with the improvement driven by an increase in net income and by lower use of working capital. Capital expenditures were $0.3 billion vs $0.4 billion in the prior year period, as Free cash flow¹ increased to $1.6 billion vs $1.0 billion in the prior year period. Total cash and cash equivalents were $1.0 billion as of September 27, 2026 vs $1.1 billion as of

December 28, 2025. Total debt was $8.2 billion as of September 27, 2026 vs $8.5 billion as of December 28, 2025.

2026 Restructuring Initiative

As previously disclosed, on February 17, 2026, the Company’s Board of Directors approved an initiative (the “2026 Restructuring Initiative”) that aims to optimize its operating model, transform its supply chain, reduce complexity, and drive operational efficiencies, while strengthening core capabilities. The Initiative is expected to result in pre-tax restructuring expenses and other charges totaling approximately $250 million in fiscal year 2026.

No Conference Call

Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call. This press release will be posted on the Company’s website at investors.kenvue.com.

About Kenvue

Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID®

Brand, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at kenvue.com.¹

Non-GAAP Financial Measures

The Company uses certain non-GAAP financial measures to supplement the financial measures prepared in accordance with U.S. GAAP. There are limitations to the use of the non-GAAP financial⁴ measures presented herein. These non-GAAP financial measures are not prepared in accordance with U.S. GAAP, nor do they have any standardized meaning under U.S. GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way the Company calculates such measures. Accordingly, the non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies. The Company cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most directly comparable U.S. GAAP measure. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. These non-GAAP financial measures should be considered supplements to, not substitutes for, or superior to, the corresponding financial measures calculated in accordance with U.S. GAAP.

The Company believes the presentation of these measures is relevant and useful for investors because it allows investors to view performance in a manner similar to the method used by management. The Company believes these measures help improve investors’ ability to understand the Company’s operating performance and makes it easier to compare the Company’s results with other companies. In addition, the Company believes these measures are also among the primary measures used externally by the Company’s investors, analysts, and peers in its industry for purposes of valuation and comparing the operating performance of the Company to other companies in our industry.

Below are definitions and the reconciliation to the most closely related GAAP measures for the non-GAAP measures used in this press release.

Adjusted diluted earnings per share

: We define Adjusted diluted earnings per share as Adjusted net income divided by the weighted average number of diluted shares outstanding. Management views this non-GAAP measure as useful to investors as it provides a supplemental measure of the Company’s performance over time.

Adjusted EBITDA margin... (truncated)incurred in connection with the pending transaction with Kimberly-Clark (“Pending Transaction and other related costs”), costs associated with the Skillman sale-leaseback, and the impact of the deferred transfer of certain assets and⁵ liabilities from Johnson & Johnson in certain jurisdictions (the “Deferred Markets”). We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of U.S. GAAP Net sales. Management believes this non-GAAP measure is useful to investors as it provides a supplemental perspective to the Company’s operating efficiency over time.

Adjusted effective tax rate

: We define Adjusted effective tax rate as U.S. GAAP Effective tax rate adjusted for the tax effects on special item adjustments including amortization of intangible assets, restructuring expenses and operating model optimization initiatives, Separation-related costs, conversion of stock-based awards, Founder Shares, Pending Transaction and other related costs, and costs associated with the Skillman sale-leaseback. We also exclude taxes related to the Deferred Markets. Management believes this non-GAAP measure is useful to investors as it provides a supplemental measure of the Company’s performance over time.

Adjusted gross profit margin

: We define Adjusted gross profit margin as U.S. GAAP Gross profit margin adjusted for amortization of intangible assets, Separation-related costs, conversion of stock-based awards, Founder Shares, operating model optimization initiatives, and Pending Transaction and other related costs. Management believes this non-GAAP measure is useful to investors as it provides a supplemental perspective to the Company’s operating efficiency over time.

Adjusted net income

: We define Adjusted net income as U.S. GAAP Net income adjusted for amortization of intangible assets, restructuring expenses and operating model optimization initiatives, Separation-related costs, conversion of stock-based awards, Founder Shares, Pending Transaction and other related costs, costs associated with the Skillman sale-leaseback, the impact of the Deferred Markets, and their related tax impacts (i.e., special items). Adjusted net income excludes the impact of items that may obscure trends in our underlying performance. Management believes this non-GAAP measure is useful to investors as the Company uses Adjusted net income for strategic decision making, forecasting future results, and evaluating current performance.

Adjusted operating income

: We define Adjusted operating income as U.S. GAAP Operating income adjusted for amortization of intangible assets, restructuring expenses and operating model optimization initiatives, Separation-related costs, conversion of stock-based awards, Founder Shares, Pending Transaction and other related costs, costs associated with the Skillman sale-leaseback, and the impact of the Deferred Markets. Management believes this non-GAAP measure is useful to investors as management uses Adjusted operating income to assess the Company’s financial performance.⁶

Adjusted operating income margin

: We define Adjusted operating income margin as Adjusted operating income as a percentage of U.S. GAAP Net sales. Management believes this non-GAAP measure is useful to investors as it provides a supplemental perspective to the Company’s operating efficiency over time.

Free cash flow

: We define Free cash flow as U.S. GAAP Net cash flows from operating activities adjusted for purchases of property, plant, and equipment. Management believes this non-GAAP measure is useful to investors as it provides a view of the Company’s liquidity after deducting capital expenditures, which are considered a necessary component of our ongoing operations.

Organic sales

: We define Organic sales as U.S. GAAP Net sales excluding the impact of changes in foreign currency exchange rates and the impact of acquisitions and divestitures. We report changes in Organic sales on a period-over-period basis. Management believes reporting period-over-period changes in Organic sales provides investors with supplemental information that is useful in assessing the Company’s results of operations by excluding the impact of certain items that we believe do not directly reflect our underlying operations.

Market Share Information

The Company uses market share and related metrics, including Average Weekly Recommendations, as indicators to assess business performance and trends. Market share references in this press release are derived from a combination of consumption and market share data provided by third-party vendors and internal estimates. Unless otherwise indicated, such references represent the percentage of the dollar value of sales of our products, relative to all product sales in the category in the countries in which the Company operates and purchases data.

Market share data is subject to inherent limitations, including the availability and timing of underlying information. In particular, market share data is not generally available for certain retail channels. The Company measures market share through the most recent period for which market share data is available, which generally reflects a lag time of one or two months. While the Company believes the third-party vendors it uses to provide data are reliable, it has not independently verified the accuracy or completeness of such data or its underlying assumptions. In addition, the Company’s reported market share data may differ from that reported by other companies due to differences in category definitions, geographic scope, internal estimates and other factors.

Financial statements

Income Statement

Fiscal Three Months Ended — (Unaudited; Dollars in Millions, Except Per Share Data; Shares in Millions)

Fiscal Three Months Ended – September 27, 2026Fiscal Three Months Ended – September 28, 2025Fiscal Nine Months Ended – September 27, 2026Fiscal Nine Months Ended – September 28, 2025
Net sales3,8863,76411,75011,344
Cost of sales1,5721,5384,8334,689
Gross profit2,3142,2266,9176,655
Selling, general, and administrative expenses1,5691,5124,5594,553
Restructuring expenses3384163204
Other operating expense, net612319
Operating income7066292,1721,879
Other expense, net8101926
Interest expense, net8993274281
Income before taxes6095261,8791,572
Provision for taxes179128519432
Net income4303981,3601,140
Net income per share
Basic0.220.210.710.59
Diluted0.220.210.710.59
Weighted-average number of shares outstanding
Basic1,9211,9181,9191,917
Diluted1,9261,9231,9231,925

Income Statement

Segment Adjusted operating income for the periods presented was as follows:

Adjusted Operating Income – Fiscal Three Months Ended – September 27, 2026Adjusted Operating Income – Fiscal Three Months Ended – September 28, 2025Adjusted Operating Income – Fiscal Nine Months Ended – September 27, 2026Adjusted Operating Income – Fiscal Nine Months Ended – September 28, 2025
Self Care Adjusted operating income5375201,6741,613
Skin Health and Beauty Adjusted operating income149137503378
Essential Health Adjusted operating income315307929897
Total1,0019643,1062,888
Reconciliation to Adjusted operating income (non-GAAP):
Depreciation(1)7775234226
General corporate/unallocated expenses7182210251
Other operating expense, net612319
Other—impact of Deferred Markets-4-5-25-30
Adjusted operating income (non-GAAP)8518112,6642,422
Reconciliation to Income before taxes:
Amortization of intangible assets(2)6466193193
Separation-related costs(4)6171679
Restructuring expenses and operating model optimization initiatives(3)4197188232
Conversion of stock-based awards115
Other—impact of Deferred Markets452530
Founder Shares-434
Pending Transaction and other related costs(5)2860
Skillman sale-leaseback26
Operating income7066292,1721,879
Other expense, net8101926
Interest expense, net8993274281
Income before taxes6095261,8791,572

Income Statement

Fiscal Three Months Ended September 27, 2026 — The following tables present reconciliations of GAAP to non-GAAP for the periods presented: (in millions)

Fiscal Three Months Ended September 27, 2026 – As ReportedFiscal Three Months Ended September 27, 2026 – As ReportedFiscal Three Months Ended September 27, 2026 – AdjustmentsFiscal Three Months Ended September 27, 2026 – As AdjustedFiscal Three Months Ended September 27, 2026 – As Adjusted
Net sales3,8863,886
Gross profit2,314752,389
Gross profit margin59.5%61.5%
Operating income706145851
Operating income margin18.2%21.9%
Net income430138568
Net income margin11.1%14.6%
Interest expense, net89
Provision for taxes179
Depreciation and amortization141
EBITDA (non-GAAP)83981920
EBITDA margin (non-GAAP)21.6%23.7%

Income Statement

The following tables present reconciliations of GAAP to non-GAAP for the periods presented:

Cost of Sales(a)SG&A/Restructuring ExpensesOther Operating Expense, NetProvision for TaxesTotal
Detail of Adjustments
Amortization of intangible assets(2)6464
Restructuring expenses(3)3333
Operating model optimization initiatives(3)628
Separation-related costs, conversion of stock-based awards, and Founder Shares(4)426
Pending Transaction and other related costs(5)12728
Skillman sale-leaseback22
Impact of Deferred Markets—minority interest expense11
Impact of Deferred Markets—provision for taxes3-3
Tax impact on special item adjustments-4-4
Total75138
Cost of sales less amortization11

Income Statement

The following tables present reconciliations of GAAP to non-GAAP for the periods presented:

Cost of Sales(a)SG&A/Restructuring ExpensesOther Operating Expense, NetProvision for TaxesTotal
Detail of Adjustments
Amortization of intangible assets(2)6666
Restructuring expenses(3)8484
Operating model optimization initiatives(3)8513
Separation-related costs, conversion of stock-based awards, and Founder Shares(4)5914
Impact of Deferred Markets—minority interest expense22
Impact of Deferred Markets—provision for taxes3-3
Tax impact on special item adjustments-39-39
Total79140
Cost of sales less amortization13

Income Statement

Fiscal Nine Months Ended September 27, 2026 — The following tables present reconciliations of GAAP to non-GAAP for the periods presented: (in millions)

Fiscal Nine Months Ended September 27, 2026 – As ReportedFiscal Nine Months Ended September 27, 2026 – As ReportedFiscal Nine Months Ended September 27, 2026 – AdjustmentsFiscal Nine Months Ended September 27, 2026 – As AdjustedFiscal Nine Months Ended September 27, 2026 – As Adjusted
Net sales11,75011,750
Gross profit6,9172297,146
Gross profit margin58.9%60.8%
Operating income2,1724922,664
Operating income margin18.5%22.7%
Net income1,3604181,778
Net income margin11.6%15.1%
Interest expense, net274
Provision for taxes519
Depreciation and amortization427
EBITDA (non-GAAP)2,5802992,879
EBITDA margin (non-GAAP)22%24.5%

Income Statement

The following tables present reconciliations of GAAP to non-GAAP for the periods presented:

Cost of Sales(a)SG&A/Restructuring ExpensesOther Operating Expense, NetProvision for TaxesTotal
Detail of Adjustments
Amortization of intangible assets(2)193193
Restructuring expenses(3)163163
Operating model optimization initiatives(3)20525
Separation-related costs, conversion of stock-based awards, and Founder Shares(4)12820
Pending Transaction and other related costs(5)45660
Skillman sale-leaseback66
Impact of Deferred Markets—minority interest expense1010
Impact of Deferred Markets—provision for taxes15-15
Tax impact on special item adjustments-59-59
Total229418
Cost of sales less amortization36

Income Statement

Fiscal Nine Months Ended September 28, 2025 — The following tables present reconciliations of GAAP to non-GAAP for the periods presented: (in millions)

Fiscal Nine Months Ended September 28, 2025 – As ReportedFiscal Nine Months Ended September 28, 2025 – As ReportedFiscal Nine Months Ended September 28, 2025 – AdjustmentsFiscal Nine Months Ended September 28, 2025 – As AdjustedFiscal Nine Months Ended September 28, 2025 – As Adjusted
Net sales11,34411,344
Gross profit6,6552336,888
Gross profit margin58.7%60.7%
Operating income1,8795432,422
Operating income margin16.6%21.4%
Net income1,1404231,563
Net income margin10%13.8%
Interest expense, net281
Provision for taxes432
Depreciation and amortization419
EBITDA (non-GAAP)2,2723502,622
EBITDA margin (non-GAAP)20%23.1%

Income Statement

The following tables present reconciliations of GAAP to non-GAAP for the periods presented:

Cost of Sales(a)SG&A/Restructuring ExpensesOther Operating Expense, NetProvision for TaxesTotal
Detail of Adjustments
Amortization of intangible assets(2)193193
Restructuring expenses(3)204204
Operating model optimization initiatives(3)20828
Separation-related costs, conversion of stock-based awards, and Founder Shares(4)206888
Impact of Deferred Markets—minority interest expense1212
Impact of Deferred Markets—provision for taxes18-18
Tax impact on special item adjustments-102-102
Total233423
Cost of sales less amortization40

Balance Sheet

From the 10-Q · September 27, 2026 — (Unaudited; Dollars in Millions, Except Per Share Data; Shares in Thousands)

September 27, 2026December 28, 2025
Current assets
Cash and cash equivalents1,0391,062
Trade receivables, less allowances for credit losses ($15 and $26 as of September 27, 2026 and December 28, 2025, respectively)2,5042,382
Inventories1,8151,666
Prepaid expenses and other receivables410432
Other current assets171155
Total current assets5,9395,697
Property, plant, and equipment, net2,2332,212
Intangible assets, net8,3308,694
Goodwill9,2519,509
Deferred taxes on income244237
Other assets674727
Total Assets26,67127,076
Current liabilities
Loans and notes payable1,1211,453
Accounts payable2,6852,473
Accrued liabilities1,5221,159
Accrued rebates, returns, and promotions770755
Accrued taxes on income118105
Total current liabilities6,2165,945
Long-term debt7,0857,071
Deferred taxes on income2,2972,354
Employee-related obligations341340
Other liabilities570601
Total liabilities16,50916,311
Stockholders’ Equity
Common stock, $0.01 par value, 12,500,000 shares authorized; 1,941,266 and 1,920,880 shares issued and outstanding as of September 27, 2026, respectively; 1,936,502 and 1,916,115 shares issued and outstanding as of December 28, 2025, respectively1919
Additional paid-in capital16,43716,348
Treasury stock, 20,387 shares at cost as of September 27, 2026 and December 28, 2025-439-439
Accumulated deficit-447-204
Accumulated other comprehensive loss-5,408-4,959
Total stockholders’ equity10,16210,765
Total Liabilities and Stockholders’ Equity26,67127,076

Cash Flow

Fiscal Nine Months Ended (in billions)

Fiscal Nine Months Ended – September 27, 2026Fiscal Nine Months Ended – September 28, 2025
Net cash flows from operating activities1.91.3
Purchases of property, plant, and equipment-0.3-0.4
Free cash flow (non-GAAP)1.61

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements about management’s⁷... (truncated)tatements regarding the pending transaction with Kimberly-Clark. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates. Risks and uncertainties include, but are not limited to: the inability to execute on Kenvue’s business development strategy; inflation and other economic factors, such as interest rate and currency exchange rate fluctuations, as well as existing or proposed tariffs and other constraints on trade both in the U.S. and in foreign markets; the ability to successfully manage local, regional, or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow Kenvue to effect any dividend payments; Kenvue’s ability to maintain satisfactory credit ratings and access capital markets, which could adversely affect its liquidity, capital position, and borrowing costs; competition, including technological advances, new products, and intellectual property attained by competitors; challenges inherent in new product research and development; uncertainty of commercial success for new and existing products and digital capabilities; challenges to intellectual property protections, including counterfeiting; the ability of Kenvue to successfully execute strategic plans, including the 2026 Restructuring Initiative and any other restructuring or cost-saving initiatives; the impact of business combinations and divestitures, including any ongoing or future transactions; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations and other stakeholder requirements; changes in behavior and spending patterns of consumers; natural disasters, acts of war, or terrorism, catastrophes, or epidemics, pandemics, or other disease outbreaks; financial instability of international economies and legal systems and sovereign risk; the inability to realize the benefits of the separation from Kenvue’s former parent, Johnson & Johnson; the risk of disruption or unanticipated costs in connection with the separation; the Company’s inability to consummate the pending transaction with Kimberly-Clark due to, among other things, market, regulatory, and other factors; the potential for disruption to the Company’s business resulting from the pending transaction with Kimberly-Clark; and potential adverse effects on the Company’s stock price from the suspension or consummation of the pending transaction with Kimberly-Clark. A further list and descriptions of these risks, uncertainties, and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other filings, available at investors.kenvue.com or on request from Kenvue. Any forward-⁸ looking statement made in this release speaks only as of the date of this release. Kenvue undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or developments or otherwise.

Contacts

Investor Relations:

Kenvue_IR@kenvue.com

Media Relations: media@kenvue.com⁹

Kenvue Inc.

Condensed Consolidated Statements of Operations

(Unaudited; Dollars in Millions, Except Per Share Data; Shares in Millions)¹⁰

Organic Sales Change

The following tables present a reconciliation of the change in Net sales, as reported, to the change in Organic sales, a non-GAAP measure, for the periods presented:

(1)

Acquisitions and divestitures did not impact the reported Net sales change.

(2)

Price/Mix reflects value realization.

Total Segment Net Sales and Adjusted Operating Income

Segment Net sales for the periods presented were as follows:¹¹

Segment Adjusted operating income for the periods presented was as follows:¹²

Non-GAAP Financial Information

The following tables present reconciliations of GAAP to non-GAAP for the periods presented:¹³¹⁴¹⁵

(1)

Depreciation consists of depreciation of property, plant, and equipment and amortization of integration and development costs capitalized in connection with cloud computing arrangements.

(2)

Relates to the amortization of definite-lived intangible assets (primarily trademarks, trade names, and customer lists) over their estimated useful lives.¹⁶

(3)

Restructuring expenses and operating model optimization initiatives in the fiscal three and nine months ended September 27, 2026 related to the 2026 Restructuring Initiative and in the fiscal three and nine months ended September 28, 2025 related to the 2024 Multi-year Restructuring Initiative and were composed of the following:

Restructuring expenses and operating model optimization initiatives include accelerated depreciation expense on assets related to the 2026 Restructuring Initiative for the fiscal three and nine months ended September 27, 2026.

(4)

Separation-related costs relate to non-recurring costs incurred in connection with our establishment of Kenvue as a standalone public company. Separation-related costs, the impact of the conversion of stock-based compensation awards, and the incremental stock-based compensation from the issuance of the Founder Shares, were composed of the following:

(5)... (truncated)advisory fees, legal costs, professional service costs, and other related costs.

The following table presents reconciliations of the Effective tax rate, as reported, to Adjusted effective tax rate for the periods presented:¹⁷

The following table presents a reconciliation of Diluted earnings per share, as reported, to Adjusted diluted earnings per share for the periods presented:

The following table presents a reconciliation of Net cash flows from operating activities, as reported, and Purchases of property, plant, and equipment, as reported, to Free cash flow for the periods presented:

Note: Numbers may not foot due to rounding.

Other Supplemental Financial Information

The following table presents the Company’s Net sales by geographic region for the periods presented:

The following table presents the Company’s Research and development expenses for the periods presented. Research and development expenses are included within Selling, general, and administrative expenses.¹⁸

The following table presents the Company’s Cash and cash equivalents, Total debt, and Net debt balance as of the periods presented:

Note: Numbers may not foot due to rounding.¹⁹

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.